Alector (ALEC) Stock Price, News & Analysis

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALEC shares.
View ALEC analyst ratings or view top-rated stocks.

7 equities research analysts have issued twelve-month target prices for Alector's stock. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 188.3% from the stock's current price.
View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts.

Alector's stock was trading at $7.98 at the start of the year. Since then, ALEC shares have decreased by 37.0% and is now trading at $5.03.
View the best growth stocks for 2024 here.

Alector saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,470,000 shares, an increase of 10.6% from the March 15th total of 5,850,000 shares. Based on an average daily volume of 690,900 shares, the days-to-cover ratio is presently 9.4 days. Currently, 8.9% of the company's shares are sold short.
View Alector's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ALEC earnings forecast.

Alector, Inc. (NASDAQ:ALEC) issued its earnings results on Tuesday, February, 27th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.31. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $8.35 million. Alector had a negative net margin of 134.34% and a negative trailing twelve-month return on equity of 77.15%.

iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio.

Alector issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60.0 million-$70.0 million, compared to the consensus revenue estimate of $100.9 million.

4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO).

Alector (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector's stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman.
View institutional ownership trends.

Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.